FK506 increases peripheral nerve regeneration after chronic axotomy but not after chronic Schwann cell denervation

Experimental Neurology

Volumn 175, Issue 1, 2002, Pages 127-137

  Sulaiman, Olawale A R ^a   Voda, Jan ^b   Gold, Bruce G ^b   Gordon, Tessa ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Chronic denervation; Functional recovery; Motoneurons; PNS injury and regeneration; PNS myelination; Rate of axonal regeneration; Retrograde labeling; Sciatic nerve

Indexed keywords

TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LABELING; CHRONIC DISEASE; CONTROLLED STUDY; DENERVATION; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; MALE; MOTONEURON; MYELIN SHEATH; MYELINATED NERVE; NERVE FIBER REGENERATION; NERVE FIBER TRANSECTION; NONHUMAN; PERIPHERAL NERVE INJURY; PERONEUS NERVE; PRIORITY JOURNAL; RAT; SCHWANN CELL; THICKNESS; TIBIAL NERVE;

EID: 0036255020     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.2002.7878     Document Type: Article

References (45)

1. A quantitative histology of Wallerian degeneration: Nuclear population in rabbit sciatic nerve
2. Brief electrical stimulation promotes the speed and accuracy of motor axonal regeneration
3. The effects of FK506 on dorsal column axons following spinal cord injury in adult rats: Neuroprotection and local regeneration
4. The dose-dependent fascilitation and inhibition of peripheral nerve regeneration by exogenous brain derived neurotrophic factor
5. Calcineurin is a key signaling enzyme in T lymphocyte activation and the target of immunosuppressive drugs cyclosporin and FK506
6. A novel immunophilin ligand: Distinct branching effects on dopaminergic neurons in culture and neurotrophic actions after oral administration in an animal model of Parkinson's disease
7. Immunophilin ligands and GDNF enhance neurite branching or elongation from developing dopamine neurons in culture
8. FK506 accelerates functional recovery following nerve grafting in a rat model
9. The immunosuppressant FK506 ameliorates ischemic damage in the rat brain
10. Human hand allograft: Report on first 6 months
11. Contributing factors to poor functional recovery after delayed nerve repair: Prolonged axotomy
12. Contributing factors to poor functional recovery after delayed nerve repair: Prolonged muscle denervation
13. The cellular and molecular basis of peripheral nerve regeneration
14. Immunophilin FK506 binding protein 52 (not FK506 binding protein 12) mediates the neurotrophic action of FK506
15. Efficacy of delayed or discontinous FK506 administration on nerve regeneration in the rat sciatic nerve crush model: Lack of evidence for a conditioning lesion-like-effect
16. The immunosuppressant FK506 increases the rate of axonal regeneration in rat sciatic nerve
17. The immunosuppressant drug FK506 increases functional recovery and nerve regeneration following peripheral nerve injury
18. The immunosuppressant drug FK506 increases GAP-43 mRNA levels in axotomized sensory neurons
19. Neuroimmunophilin ligands: Evaluation of their therapeutic potential for the treatment of neurological disorders
20. The use of FK-506 for small intestine allo-transplantation: Inhibition of acute rejection and prevention of fatal graft-versus-host disease
21. Successful hand transplantation: One year follow-up
22. Acceleration of peripheral nerve regeneration following FK506 administration
23. Suppressive effect of FK506, a novel immunosuppressant, against MPTP-induced dopamine depletion in the striatum of young C57BL/6 mice
24. FK506 promotes functional recovery in crushed rat sciatic nerve
25. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
26. Increased expression of FK506 binding protein during peripheral nerve regeneration
27. Immunosuppressant FK506 promotes neurite outgrowth in cultures of PC12 cells and sensory ganglia
28. Neuronal regeneration enhances the expression of the immunophilin FKBP-12
29. New directions in peripheral nerve surgery
30. Tacrolimus (FK506) increases neuronal expression of GAP-43 and improves functional recovery after spinal cord injury in rats
31. Progress in peripheral nerve reconstruction
32. Iontophoretic injection of fluoro-gold and other fluorescent tracers
33. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischemia
34. FK506: A potential breakthrough in immunosuppression
35. FK506 for liver, kidney, and pancreas transplantation
36. High brain densities of the immunophilin FKBP colocalized with calcineurin
37. Effects of short- and long-term Schwann cell denervation on peripheral nerve regeneration, myelination and size
38. Transforming growth factor-β and forskolin attenuate the adverse effects of long-term Schwann cell denervation on peripheral nerve regeneration in vivo
39. FK506 increases motor nerve regeneration after chronic axotomy but not after chronic Schwann cell denervation
40. Denervation atrophy of the distal stump of a severed nerve
41. Response of facial and rubrospinal neurons to axotomy: Changes in mRNA expression for cytoskeletal proteins and GAP-43
42. FK506 increases nerve regeneration following chronic axotomy but not chronic denervation
43. Comparative dose-dependent study of FK506 and cyclosporin A on the rate of axonal regeneration in the rat sciatic nerve
44. FK506 increases the regeneration of spinal cord axons in a predegenerated peripheral nerve autograft
45. The mechanism of action of FK506 and cyclosporin A